This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The article by the Drug-Resistant Streptococcus pneumoniae (DRSP) Therapeutic Working Group¹ on the management of community-acquired pneumonia (CAP) has generated great interest. This week I received a brochure promoting azithromycin with a copy of the DRSP Therapeutic Working Group article enclosed. The brochure introduced the article as follows: "The Centers for Disease Control (CDC) Therapeutic Working Group recommends macrolides as first-line therapy" for CAP. The DRSP Therapeutic Working Group met at the CDC in 1998, but is not identified as a part of the CDC. Does the article constitute official CDC recommendations?

Newer quinolones (levofloxacin, gatifloxacin, moxifloxacin, etc) are effective for adults with CAP and may reduce mortality when compared with other agents.^2-4 The Infectious Disease Society of America, Alexandria, Va, recommends empiric quinolone monotherapy as a first-line choice for adult inpatients and outpatients.⁵ Some authorities prefer quinolones over other agents for adults with risk factors for pneumococcal infection (eg, . . . [Full Text of this Article]